Navigation Links
Ten years later, Dolly is still making headlines

The lead researcher for the team who - 10 years ago - created the cloned sheep "Dolly," will kick off the 2006 American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference in Boston, June 18-21. At the meeting, nearly two-thousand of the world's leading scientists will discuss a variety of critical issues affecting pharmaceutical biotechnology including Biogenerics, a field that is being hailed as the next revolution in healthcare.

"At AAPS, we are committed to tackling the latest issues ?even the toughest issues ?and exposing our members to disparate points of view so they ?as the most highly trained scientists in the world ?can draw their own conclusions," said John Lisack, AAPS executive director. "With topics like cloning and biogenerics headlining this year's event, there is no more exciting and challenging time to be in the field of pharmaceutical sciences than now."

The following topics will headline this year's meeting:

Creator of "Dolly" and world-renowned scientists share insight

Making his first U.S. appearance since his book, About Dolly, hit shelves earlier this month, Dr. Ian Wilmut, the lead researcher of a team of scientists who were first to successfully clone an animal, Dolly the sheep, ten years ago, will speak about his plans to clone embryos to alter disease genes in humans. Wilmut will be joined by two other leaders in biotechnology research, Dr. Kevin Eggan of the Harvard Stem Cell Institute, where plans were just announced to create the world's first cloned human embryonic stem cells, and Dr. Burt Adelman of Biogen Idec, the company that produces the recently re-approved multiple sclerosis drug, Tysabri. The Plenary Session is Monday, June 19 from 8:30 a.m. to 11:30 a.m. at the Hynes Convention Center.

Biogenerics ?The next revolution in health care?

Generic biopharmaceutical drugs, or biogenerics, are widely available in Europe and Australia, but the first biogeneric was just approved last month in the United States by the Food and Drug Administration (FDA). This approval has opened a pandora's box of issues. Biopharmaceutical medications are some of the most expensive medicines on the market. Approving generic formulas, therefore, has the potential to put once inaccessible drugs within the reach of millions more people, but at what cost? At the Boston meeting, there will be an Open Forum on Sunday, June 18 from 8 a.m. to 5:15 p.m. in the Hynes Convention Center to discuss the various regulatory, scientific and ethical issues surrounding generic biopharmaceuticals, as well as:

  • Why is the FDA slow to approve biogenerics?
  • What are the risks of a biogeneric drug, like a human growth hormone, being used for the off-label purpose of anti-aging?
  • With $20B of biotechnology-derived product losing patent protection over the next few years, how will the FDA handle this influx of legal and regulatory challenges?

National Biotechnology Conference

The AAPS National Biotechnology Conference is an annual event incorporating all aspects of pharmaceutical biotechnology and providing an open forum for discussion of industry topics. The conference will take place June 18?1 at the John B. Hynes Convention Center, Boston, Mass.


'"/>

Source:American Association of Pharmaceutical Scientists


Related biology news :

1. Artifical cornea lets woman blind 20 years see
2. Retrovirus struck ancestors of chimpanzees and gorillas millions of years ago, but did not affect ancestral humans
3. Hunger in America rises by 43 percent over last five years
4. Picky female frogs drive evolution of new species in less than 8,000 years
5. Bone marrow stem cells may heal hearts even years after heart attacks
6. Carbon cycle was already disrupted millions of years ago
7. Ancient ants arose 140-168 million years ago
8. Bt cotton in China fails to reap profit after seven years
9. UCLA scientists strengthen case for life more than 3.8 billion years ago
10. Allergy battle could be won in five years, says scientist
11. Scientists describe new African monkey genus ?first in 83 years
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of ā‚¬500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... , ... December 07, 2016 , ... ... has concluded that ā€œin the setting of previously treated, advanced pancreatic cancer, liquid ... defining the optimal patient population and timing of blood sampling may improve the ...
(Date:12/7/2016)... -- Neogen Corporation (NASDAQ: NEOG ) announced ... as its chief science officer ā€” a new position ... Neogen effective Jan. 1. Kephart has served ... of Thermo Fisher Scientific, as well as animal health ... industry experience also includes the management of a team ...
(Date:12/7/2016)... - Zenith Capital Corp. ("Zenith" or the "Company") announces webcast details ... Company,s Annual and Special Meeting. The Zenith ... Thursday, December 15, 2016 at Mount Royal ... Mount Royal Gate SW, Calgary, Alberta , ... management information circular, containing the matters to be considered at ...
(Date:12/7/2016)... , Dec. 7, 2016  Biocom, the association for the ... statement below following passage of 21 st Century Cures ... November 30 by a 392-26 vote and in the Senate ... be attributed to Joe Panetta , president & CEO ... will give hope to millions of patients around the world. ...
Breaking Biology Technology: